Histone Deacetylase Inhibitors in Diagnosis and Treatment of Thyroid Neoplasms
Description of Invention:
The invention disclosed is novel approaches to thyroid cancer therapy. These approaches include methods to enhance thyroid specific gene expression, for example methods to enhance expression of thyroglobulin and/or the Na/I symporter in thyroid cancer cells. Enhanced expression of thyroid-specific genes promotes cellular differentiation and reduces biologically aggressive behavior such as invasion and metastasis. In addition, enhanced expression of thyroglobulin and/or the Na/I symporter increases the ability of thyroid cancer cells to concentrate iodine, thereby making the cells more susceptible to radioactive iodine therapy. Also disclosed are methods for detecting thyroid neoplasms in a subject, by administering a therapeutically effective amount of a histone deacetylase inhibitor, administering a detectable agent whose uptake or concentration in thyroid cells is increased by administration of the histone deacetylase inhibitor, and detecting the detectable agent.
Inventors:
Tito A. Fojo (NCI) Susan Bates (NCI)
Patent Status:
DHHS Reference No. E-286-2000/0 --
U.S. Provisional Application No. 60/260,733 filed 10 Jan 2001
PCT Application No. PCT/US02/00714 filed 09 Jan 2002, which published as WO 02/055688 on 18 Jul 2002
U.S. Patent Application No. 10/250,320 filed 26 Jun 2003
Portfolios: Cancer
Cancer -Diagnostics Cancer -Therapeutics
For Additional Information Please Contact: John Stansberry Ph.D.
NIH Office of Technology Transfer
6011 Executive Boulevard, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-5236
Email: stansbej@mail.nih.gov
Fax: (301) 402-0220
